Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) stock fell -3.19% on Wednesday to $8.95 against a previous-day closing price of $9.25. With 2.78 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.65 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $9.18 whereas the lowest price it dropped to was $8.31. The 52-week range on RXRX shows that it touched its highest point at $14.18 and its lowest point at $4.54 during that stretch. It currently has a 1-year price target of $15.50.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RXRX was up-trending over the past week, with a rise of 66.45%, but this was up by 73.21% over a month. Three-month performance surged to 14.08% while six-month performance fell -1.38%. The stock gained 54.40% in the past year, while it has gained 16.15% so far this year. A look at the trailing 12-month EPS for RXRX yields -1.38 with Next year EPS estimates of -1.57. For the next quarter, that number is -0.37. This implies an EPS growth rate of 8.30% for this year and -13.80% for next year.
Float and Shares Shorts:
At present, 191.62 million RXRX shares are outstanding with a float of 151.58 million shares on hand for trading. On Apr 27, 2023, short shares totaled 20.44 million, which was 10.63% higher than short shares on Mar 30, 2023. In addition to Dr. Christopher C. Gibson Ph.D. as the firm’s Co-Founder, CEO & Director, Ms. Tina Marriott Larson serves as its COO & Pres.
Institutional Ownership:
Through their ownership of 86.30% of RXRX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 35.84% of RXRX, in contrast to 26.02% held by mutual funds. Shares owned by individuals account for 24.31%. As the largest shareholder in RXRX with 13.70% of the stake, Baillie Gifford & Co. holds 25,135,530 shares worth 25,135,530. A second-largest stockholder of RXRX, The Vanguard Group, Inc., holds 10,748,375 shares, controlling over 5.86% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in RXRX, holding 9,118,782 shares or 4.97% stake. With a 8.74% stake in RXRX, the Scottish Mortgage Investment Trus is the largest stakeholder. A total of 16,029,227 shares are owned by the mutual fund manager. The Government Pension Fund – Global, which owns about 2.38% of RXRX stock, is the second-largest Mutual Fund holder. It holds 4,371,313 shares valued at 20.85 million. Vanguard US Growth Fund holds 2.17% of the stake in RXRX, owning 3,973,231 shares worth 18.95 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, RXRX reported revenue of $7.65M and operating income of -$66.19M. The EBITDA in the recently reported quarter was -$62.76M and diluted EPS was -$0.38.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RXRX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With RXRX analysts setting a high price target of $33.00 and a low target of $8.00, the average target price over the next 12 months is $14.00. Based on these targets, RXRX could surge 268.72% to reach the target high and fall by -10.61% to reach the target low. Reaching the average price target will result in a growth of 56.42% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded RXRX stock several times over the past three months with 13 Buys and 10 Sells. In these transactions, 297,733 shares were bought while 156,430 shares were sold. The number of buy transactions has increased to 84 while that of sell transactions has risen to 58 over the past year. The total number of shares bought during that period was 5,259,109 while 487,832 shares were sold.
